Honest read

Dual and triple agonists in obesity medicine

From semaglutide (GLP-1 mono) to tirzepatide (GIP/GLP-1 dual) to retatrutide (GIP/GLP-1/glucagon triple) — the engineering strategy that has produced progressively deeper weight loss with each generation. How the field got here, what each receptor arm contributes, and what the limits of receptor-stacking might be.

Field overview

The 60-second version

Modern obesity medicine has moved from GLP-1 monotherapy through GIP/GLP-1 dual agonism to triple GIP/GLP-1/glucagon agonism in roughly five years. Each generation has produced approximately 5-10 percentage points more weight loss than the prior generation, and the trajectory is reshaping standard-of-care expectations. The engineering rationale is mechanistically clean: each additional receptor arm adds biology that the prior arms don't capture. Whether the trajectory continues with quadruple agonism, what the practical limits look like, and how combination strategies (incretin + amylin, incretin + muscle-preservation antibody) compare to receptor-stacking are the open questions.

The progression in numbers

The receptor-stacking generations show progressive weight-loss depth:

  • GLP-1 mono (semaglutide): ~15% mean weight loss at 68 weeks (STEP-1).
  • GIP/GLP-1 dual (tirzepatide): ~21% at 72 weeks (SURMOUNT-1).
  • GIP/GLP-1/glucagon triple (retatrutide): ~24% at 48 weeks (Phase 2; Phase 3 ongoing).

The progression is real and consistent across multiple trials and populations. It is also the most rapid generational improvement in any pharmacotherapy class in modern medicine.

What each receptor arm actually contributes

GLP-1. Appetite suppression through hypothalamic and brainstem circuits, slowed gastric emptying, glucose-dependent insulin secretion. The foundation of the class.

GIP. Distinct adipose-tissue effects, possibly improved nausea tolerability through different central mechanisms, and contributions to insulin sensitivity that complement GLP-1's biology. The dual-agonism story added between 5-7 percentage points of weight loss to GLP-1 monotherapy.

Glucagon. Energy expenditure (raises metabolic rate), direct hepatic effects (reduces hepatic fat — the basis of efinopegdutide's NASH program), and counter-regulatory glucose effects. The challenge is balancing the glucagon arm's weight-loss-deepening effects against its glucose-raising effects, which is what made earlier dual GLP-1/glucagon programs (cotadutide) struggle to find the right risk-benefit profile.

The other dual/triple agonists in the pipeline

Beyond the headline molecules, several others are advancing:

  • Survodutide (Boehringer Ingelheim/Zealand) — GLP-1/glucagon dual.
  • Mazdutide (Innovent/Lilly) — GLP-1/glucagon dual; approved in China.
  • Pemvidutide (Altimmune) — GLP-1/glucagon dual.
  • Efinopegdutide (Hanmi/Merck) — GLP-1/glucagon dual with NASH focus.
  • HRS9531 (Hengrui) — GLP-1/GIP dual; Phase 3.
  • MariTide / Maridebart cafraglutide (Amgen) — GLP-1 + GIP antagonist (the contrarian approach: blocking GIP rather than activating it).

The MariTide approach is particularly interesting because it inverts the GIP rationale — Amgen's development hypothesis is that GIP receptor antagonism (rather than agonism) might produce comparable weight loss with less GIP-related desensitization. Whether antagonism or agonism is the right GIP strategy is one of the more interesting open scientific questions in the class.

The limits of receptor-stacking

Two practical limits constrain how far receptor-stacking can go:

  1. Tolerability stacks too. Each receptor arm contributes to GI side-effect burden; combining more arms doesn't produce indefinitely better tolerability.
  2. The biology of weight loss has floors. Beyond a certain magnitude of weight loss in adults with obesity, lean-mass preservation, nutrient deficiency risk, and gallbladder/pancreatic stress become rate-limiting concerns rather than further weight-loss depth.

The field's response to these limits has been combination strategies (GLP-1 + amylin, GLP-1 + muscle-preservation antibody) rather than ever-larger receptor-stacking molecules. The GLP-1 + amylin direction (CagriSema, the most-watched modern combination) and the GLP-1 + bimagrumab direction (the most-watched muscle-preservation combination) represent two parallel paths beyond pure receptor-stacking.

What this means for the next 3-5 years

Several things are likely:

  • Retatrutide approval is the most-watched near-term event; if Phase 3 confirms Phase 2 magnitudes, it will become the deepest approved weight-loss agent.
  • CagriSema Phase 3 will inform whether the amylin combination strategy meaningfully extends beyond what triple agonism alone produces.
  • Bimagrumab + tirzepatide Phase 3 will inform whether the muscle-preservation combination becomes standard practice.
  • Cardiovascular outcomes across the dual/triple agonist class will determine which molecules become first-line in patients with cardiometabolic disease.

What this means for you

If you're a clinician, the trajectory means that current FDA-approved options (semaglutide, tirzepatide) will likely be supplemented by retatrutide and the amylin- and muscle-preservation combinations within the next 2-3 years. Standard-of-care will continue evolving.

If you're a patient, the medications keep getting better. The question of which generation to start on (or switch to) will depend on tolerability, cost, access, and specific clinical context.

If you're following peptide pharmacology more broadly, the dual/triple agonist arc is one of the most successful protein-engineering achievements of the 2020s. The lessons about how receptor-arm selection shapes efficacy and tolerability will inform other peptide-class development for the next decade.

Primary research on the compounds

Peptide pageSemaglutide Peptide pageTirzepatide Peptide pageRetatrutide Peptide pageSurvodutide Peptide pageMazdutide Peptide pagePemvidutide

Related stacks

StackRetatrutide + Tirzepatide StackGLP-1 + Amylin Combination Therapy StackVisceral Adipose-Targeted Stack

Adjacent reads

Adjacent readWhat we've learned from the GLP-1 explosion Adjacent readRetatrutide before Phase 3: what the trials show so far

References

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
  3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/

We revise this read when major new trials publish or when our reading of the evidence shifts. Last updated: April 2026.